Skip to main content
. 2021 Mar 22;14:967–981. doi: 10.2147/IJGM.S302012

Figure 5.

Figure 5

Stratified survival analysis of ARRDC3 in ovarian cancer by TP53 mutation of OS, PFS, PPS. (A and B) Stratified survival analysis of ARRDC3 in ovarian cancer of mutation type and wild type of OS, respectively; (C and D) stratified survival analysis of ARRDC3 in ovarian cancer of mutation type and wild type of PFS, respectively; (E and F) stratified survival analysis of ARRDC3 in ovarian cancer of mutation type and wild type of PPS, respectively.